Eric Siemers

Neuroscience researcher trying to stop neurodegeneration before it starts. Opinions are my own.

[Alzheimer's Drug Discovery Foundation @TheADDF]

@Roche received CE Mark approval for the Elecsys pTau217 blood test, developed with @EliLillyandCo & powered by ADDF-funded @AlZpath’s pTau217 antibody. The approval marks another important step toward broader access to scalable Alzheimer’s diagnostics. https://t.co/ZhgwXfEFfz

[Alzforum @alzforum]

To discover new neurodegenerative disease biomarkers, plasma is less useful than cerebrospinal fluid. #alzheimersdisease @wustl https://t.co/W1nTJuvwcL

[Alzforum @alzforum]

Lipofuscin may stem from a failure of fatty protein recycling in childhood neurodegeneration, normal brain aging, and perhaps #alzheimersdisease and related dementias. @Yale https://t.co/kamozA6I7n

[Alzforum @alzforum]

Stopping the complement cascade nearly prevents vascular damage in mice given amyloid immunotherapy. #alzheimersdisease #ADPD2026 @BrighamWomens @adpd2026 https://t.co/NKgPL36VPG

[Eric Siemers @ers_net]

Interesting poster at AAN comparing Centiloid values to visual read results on amyloid PET scans.

[Acumen Pharmaceuticals, Inc. @AcumenPharm]

For the third year we are honored to support the @alzassociation 's "Walk to End Alzheimer’s" campaign.

If you’d like to learn more about how you can support the Acumen team, click the link below: https://t.co/o1YH1crAtv

#EndAlz #TeamAcumen #WalkToEndAlzheimers

[Alzforum @alzforum]

Plasma p-tau217 is changing diagnostic testing for Alzheimer’s. Primary care doctors are using it. A startup can speed up clinical workups with in-home testing. Many clinicians are not yet on board. @Memorial_Owosso @ucl @ClevelandClinic @lunduniversity https://t.co/Ro6IT9EMHS

[Joanne Pike, DrPH @joannepikedrph]

Our 2025 Alzheimer’s Disease Facts and Figures is a call to action – to do more, to make more progress, and to give people more reasons to believe that our vision of a world without Alzheimer’s and all other dementia is possible.

[CTAD @CTADconference]

Important article for the field available in open access: Donanemab: Appropriate use recommendations. G.D. Rabinovici et al. https://t.co/i1ud9diRtj…
#Donanemab @jpreventionalz1

[Eric Siemers @ers_net]

Elected not to cancel this X account but look for me on BS @esiemers. Enough is enough.

[Eric Siemers @ers_net]

Federal Register Blackout Blocks NIH Funding | MedPage Today https://t.co/SL8rVlCG7i

[Donna Wilcock @Wilcock_v2]

On behalf of all of my co-authors, I am sharing a collective response to the book "Doctored" by Charles Piller and in response to his NYT article promoting the book. @ApostolovaLiana @grinberg_t @holtzman4 @lab_lamb @clemere99 @MaluTansey @ers_net et al. Full author list shown.
https://t.co/qKKAAhhMxc

[Eric Siemers @ers_net]

FDA Approves New IV Maintenance Dosing for Alzheimer Treatment Lecanemab https://t.co/Zj4ljXAAjz

[Eric Siemers @ers_net]

A Country Doctor, But Oh So Much More: Francisco Lopera, 73 | ALZFORUM https://t.co/ojdCyypr8k

[Prof Cath Mummery @cathmummery]

Today’s @Telegraph first to report MHRA approval of #Leqembi - the first drug to show slowing decline of #Alzheimers. Not a wonder drug but the beginning of us having treatments that change the course of disease.

[Eric Siemers @ers_net]

Excellent discussion of rapid advancements in AD blood tests. https://t.co/eTJiIvCeTf

[USC Epstein Family ATRI @ATRI_USC]

Researchers have announced the release of a massive dataset from the Anti-Amyloid Treatment in Asymptomatic Alzheimer's (A4) and LEARN study – the first and largest clinical trial of pre-symptomatic Alzheimer's disease.

https://t.co/TCgIcc9J2k

[CTAD @CTADconference]

The #CTAD24 preliminary program is now online!
Check out our Oral Communications on Tuesday, October 29! 👇
https://t.co/2cTbSkHR4H

[Eric Siemers @ers_net]

FDA approves treatment for adults with Alzheimer’s disease | FDA https://t.co/AbetuLSqWY

[Eric Siemers @ers_net]

Blood Proteins May Foretell Parkinson’s Disease Up to Seven Years Prior | ALZFORUM https://t.co/Ud4SEUYPtL